Sea delivered strong growth in 2021 and continues to aggressively expand, but growth is set to slow in 2022 and shares have lost considerable value over the past four months.
Markets believe AstraZeneca can continue to deliver strong double-digit growth in 2022, but will the pharma giant’s outlook meet expectations this week?